A method for preparing bile acid-polyethylene glycol phospholipid compound liposome

Through the preparation of cholic acid-polyethylene glycol phospholipid compound liposomes, the intrabilic acid transporter characteristics of small intestinal epithelial cells were used to solve the problem of weak absorption capacity of ursolic acid and lumbaline, and significantly improve their biological utilization Spend.

CN118105348BActive Publication Date: 2024-11-19ZHEJIANG SHANYUHAI HEALTH CARE IND DEV CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410119036.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-29
Publication Date
2024-11-19
Estimated Expiration
2044-01-29

AI Technical Summary

Technical Problem

The poor water solubility of ursolic acid and ursolic acid leads to low bioavailability, especially in the small intestine's weak absorption capacity, and the market needs products and preparation methods to improve their bioavailability.

Method used

The preparation method of cholic acid-polyethylene glycol phospholipid compound liposomes is adopted. By mixing ursolic acid and leucoline with cholic acid, polyethylene glycol phospholipid and soybean phospholipid, nanoparticles are formed, and bile acid is used for small intestinal epithelial cells. Characteristics of intrafluorin transport proteins enhance active transport function.

Benefits of technology

The bioavailability of ursolic acid and leucoline was improved, and the absorption capacity in the small intestine was enhanced through the preparation of cholic acid-polyethylene glycol phospholipid compound liposomes, which significantly improved the bioavailability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004686076000000041
    Figure BDA0004686076000000041
  • Figure BDA0004686076000000051
    Figure BDA0004686076000000051
Patent Text Reader

Abstract

The invention discloses a bile acid-polyethylene glycol phospholipid compound liposome and a preparation method thereof, and relates to the field of medicine. The liposome comprises, by weight, 40-60 parts of ursolic acid, 40-60 parts of nuciferine, and 100-200 parts of phospholipids. The invention adopts bile acid-polyethylene glycol phospholipids to prepare modified nanoparticles, utilizes the characteristics of bile acid influx transporters in small intestinal epithelial cells, enhances active transport function, and improves the bioavailability of ursolic acid and nuciferine. The bile acid-polyethylene glycol phospholipids are composed of bile acid-polyethylene glycol phospholipids and soybean lecithin, and the three have a synergistic effect on promoting the bioavailability of ursolic acid and nuciferine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of chemistry, in particular to a method for preparing bile acid-polyethylene glycol phospholipid compound liposome. Background Art

[0002] Ursolic acid is distributed in about 7 families, 46 genera and 62 species of plants in free form or in the form of glycosides combined with sugars. Ursolic acid is insoluble in water and petroleum ether, soluble in methanol, ethanol, hot glacial acetic acid, 2% NaOH ethanol solution, and easily soluble in pyridine and dioxane. Nuciferine is an alkaloid found in blue water lilies and lotus. Nuciferine is easily soluble in organic solvents with low polarity such as benzene, ether, chloroform, and halogenated alkanes, and has good solubility in hydrophilic organic solvents such as acetone and ethanol, but has low solubility or is almost insoluble in water.

[0003] Ursolic acid and nuciferine are the main active ingredients of the compound Chinese medicine "Xuezhining". Both have poor water solubility and weak small intestinal absorption capacity, resulting in extremely low bioavailability of both. The market needs products and preparation methods that can improve the bioavailability of ursolic acid and nuciferine, and the present invention solves such problems. Summary of the invention

[0004] To overcome the deficiencies of the prior art, the present invention aims to provide a method for preparing bile acid-polyethylene glycol phospholipid compound liposomes, which improves the bioavailability of ursolic acid and nuciferol and solves the problem of weak small intestinal absorption of the active ingredients of ursolic acid and nuciferol.

[0005] In order to achieve the above object, the present invention adopts the following technical solution:

[0006] A bile acid-polyethylene glycol phospholipid compound liposome comprises, by weight, 40-60 parts of ursolic acid, 40-60 parts of nuciferine, and 100-200 parts of phospholipid.

[0007] The aforementioned bile acid-polyethylene glycol phospholipid compound liposome comprises, by weight: 50 parts of ursolic acid, 50 parts of nuciferine, and 150 parts of phospholipid.

[0008] The phospholipids in the aforementioned bile acid-polyethylene glycol phospholipid composite liposomes include a mixture of bile acid, polyethylene glycol phospholipids and soybean phospholipids.

[0009] The aforementioned bile acid-polyethylene glycol phospholipid composite liposome, the phospholipids according to the mass ratio: bile acid, polyethylene glycol phospholipids and soybean phospholipids are in a mass ratio of 1:2:5

[0010] A method for preparing bile acid-polyethylene glycol phospholipid compound liposomes comprises the following steps:

[0011] Step 1, prepare materials according to the following formula, which includes, by weight: 40-60 parts of ursolic acid, 40-60 parts of nuciferol, and 100-200 parts of phospholipids; heat ursolic acid and nuciferol in 2% acetic acid solution to 60-80° C. to completely dissolve them;

[0012] Step 2, weigh the prescribed amount of phospholipids and mix them evenly;

[0013] Step 3, placing the phospholipid in a bottle, adding 200-300 parts of chloroform thereto, evaporating and removing all the chloroform, so that a transparent and uniform film is formed on the inner wall of the bottle;

[0014] Step 4: Add ursolic acid and nuciferine dissolved in 2% acetic acid solution at 45-50°C into the bottle for hydration, and continue hydration for 1 hour.

[0015] Step 5, performing ultrasonic demulsification, and continuing ultrasonication for 10 minutes to obtain bile acid-polyethylene glycol phospholipid composite liposomes.

[0016] In the aforementioned method for preparing bile acid-polyethylene glycol phospholipid compound liposomes, the evaporation in step 3 is carried out by rotary evaporation in a 40-50° C. water bath.

[0017] In the aforementioned method for preparing bile acid-polyethylene glycol phospholipid compound liposomes, a 500W cell disruptor is used for ultrasonic demulsification.

[0018] The present invention is beneficial in that:

[0019] The present invention adopts bile acid-polyethylene glycol phospholipid to prepare modified nanoparticles, utilizes the characteristics of bile acid influx transporter in small intestinal epithelial cells, enhances active transport function, and improves the bioavailability of ursolic acid and nuciferine;

[0020] Cholic acid-polyethylene glycol phospholipids are composed of cholic acid-polyethylene glycol phospholipids and soybean lecithin, and the three have a synergistic effect on promoting the bioavailability of ursolic acid and nuciferine. DETAILED DESCRIPTION

[0021] The present invention is described in detail below with reference to specific embodiments.

[0022] Prepare materials and make samples according to the following recipes:

[0023] Example 1: 40 g ursolic acid, 40 g nuciferine, 100 g phospholipids. The mass ratio of phospholipids is: the mass ratio of bile acid, polyethylene glycol phospholipids and soybean phospholipids is 1:2:5.

[0024] Example 2: 50 g ursolic acid, 50 g nuciferine, 150 g phospholipids. The mass ratio of phospholipids is: the mass ratio of bile acid, polyethylene glycol phospholipids and soybean phospholipids is 1:2:5.

[0025] Example 3: 60 g ursolic acid, 60 g nuciferine, 200 g phospholipids. The mass ratio of phospholipids is: the mass ratio of bile acid, polyethylene glycol phospholipids and soybean phospholipids is 1:2:5.

[0026] Comparative Example 1: 50 parts of ursolic acid, 50 parts of nuciferine.

[0027] Comparative Example 2: 50 g ursolic acid, 50 g nuciferine, 100 g phospholipids. The mass ratio of phospholipids is: the mass ratio of polyethylene glycol phospholipids to soybean phospholipids is 1:5. Compared with the best example 2, bile acid is lacking.

[0028] Comparative Example 3: 50 g ursolic acid, 50 g nuciferine, 150 g phospholipids. The mass ratio of phospholipids is: the mass ratio of bile acid to polyethylene glycol phospholipids is 1:2. Compared with the optimal example 2, soybean phospholipids are missing.

[0029] Samples 1-3 and comparative samples 2-3 were prepared using the following preparation method to obtain liposomes:

[0030] Step 1, prepare materials according to the recipe of the embodiment, heat ursolic acid and nuciferol in 2% acetic acid solution to 60-80°C to completely dissolve them;

[0031] Step 2, weigh the prescribed amount of phospholipids and mix them evenly;

[0032] Step 3, placing the phospholipid in a bottle, adding 200-300 parts of chloroform thereto, evaporating and removing all the chloroform, so that a transparent and uniform film is formed on the inner wall of the bottle;

[0033] Step 4: Add ursolic acid and nuciferine dissolved in 2% acetic acid solution at 45-50°C into the bottle for hydration, and continue hydration for 1 hour.

[0034] Step five, a 500W cell disruptor is used for ultrasonic demulsification, and the ultrasound is continued for 10 minutes to obtain bile acid-polyethylene glycol phospholipid compound liposomes.

[0035] Preparation method of comparative sample 1:

[0036] Step 1, prepare materials according to the recipe of the embodiment, heat ursolic acid and nuciferol in 2% acetic acid solution to 60-80°C to completely dissolve them;

[0037] Step 2: Add ursolic acid and nuciferine dissolved in 2% acetic acid solution at 45-50°C into the bottle for hydration, and continue hydration for 1 hour.

[0038] Step three, a 500W cell disruptor was used for ultrasonication, and the ultrasonication was continued for 10 minutes to obtain a mixed solution.

[0039] 1. Caco-2 cell transmembrane absorption experiment verification

[0040] 1.1 Establishment of HPLC-MS / MS quantitative detection methodology for nuciferine

[0041] 0.1 mL of 10, 50, 100, 500, 1000 and 5000 ng / mL nuciferine solution was accurately prepared with blank Caco-2 cell culture medium, 10 μL of phenacetin internal standard solution (200 ng / mL) was added, the nuciferine solution and the internal standard solution were mixed evenly, then 3 mL of ethyl acetate was added for oscillation extraction, centrifuged for 5 min at a speed of 10000 r / min, then the upper layer of liquid was aspirated and placed in a glass tube, dried in a N2 water bath, re-dissolved with 100 μL of methanol, ultrasonically oscillated, centrifuged again for 5 min at a speed of 10000 r / min, and the upper layer of clear liquid was sampled and analyzed. When making a standard curve, the horizontal axis is the mass concentration of nuciferine, the vertical axis is the ratio of the peak area of ​​nuciferine to the internal standard, and the standard curve equation and correlation coefficient (r) were obtained.

[0042] Blank culture medium was used to prepare 10, 100, and 1000 ng / mL nuciferine solutions as quality control samples. At the same time, corresponding high, medium, and low concentrations of nuciferine methanol solutions were prepared and analyzed respectively. Then, the peak area of ​​nuciferine measured in the quality control samples was compared with the peak area measured in the methanol solution at the same concentration to obtain the recovery value of this method. In addition, high, medium, and low concentration quality control samples were injected respectively, and the ratio of the measured nuciferine to the peak area of ​​the internal standard peak was substituted into the standard curve. The calculated nuciferine concentration was compared with the concentration of nuciferine added to the quality control sample to obtain the accuracy of the method. The quality control samples were injected 5 times each within the day and between days to obtain the intra-day and inter-day precision of the samples.

[0043] Blank culture medium was used to prepare 10, 100, and 1000 ng / mL nuciferol-containing quality control samples, which were placed at 4°C and -20°C for 12 h and 24 h, respectively. After treatment according to the above method, the samples were analyzed. The ratio of the peak area of ​​nuciferol in the measured sample to that of its internal standard was substituted into the standard curve equation to obtain the nuciferol concentration. The nuciferol concentration was compared with the concentration of added nuciferol to obtain the stability of nuciferol in the sample.

[0044] 1.2 Cell density detection

[0045] This experiment uses a transmembrane resistance value of more than 200Ω / cm 2, phenol red permeability is less than 10%, and the alkaline phosphatase activity on the AP side is 10 times that on the BL side, which is used to study the transmembrane mechanism of nuciferine. First, the cells were gently washed three times after preheating PBS before starting the experiment. After the third wash, they were incubated in a cell culture incubator for 30 minutes to remove impurities on the surface of Caco-2 cells, and then the buffer was discarded. Impurities such as metabolites were washed away with PBS buffer, and then the pancreatic digestion solution that could cover the bottom was added for enzymatic hydrolysis. Observe under a microscope. When the cells become round and show signs of falling off, add 2 times the amount of serum-containing culture solution to terminate the pancreatic digestion.

[0046] At this time, the Trans-well sterile chamber was placed in the center of the culture plate under sterile conditions and marked with a marker. The culture medium in the above culture bottle was gently blown with a glass pipette to make the cells completely fall off and enter the culture medium, centrifuged for 4 minutes at a speed of 1000r / min, the supernatant was removed, and the cells were resuspended in fresh culture medium. After mixing evenly, 400μL of culture medium containing cells was added to the upper chamber of each chamber, and then the Trans-well chamber containing cells was placed in a carbon dioxide incubator for culture. After 21 days of culture, the original culture medium was discarded, 200μL of phenol red solution (concentration of 3.5μg / mL) was added to the AP side, 400μL of blank PBS buffer was added to the BL side, 100μL PBS buffer was drawn from the BL side at 0.5, 1.0, 1.5, and 2.0h, and 100μL of blank PBS buffer was added. After sampling, HPLC was used for detection, and then the values ​​were substituted into the standard curve to obtain the phenol red concentrations of the upper and lower chambers, and the phenol red permeability was calculated.

[0047] 1.3 Transmembrane transport of nuciferine in Caco-2 cells

[0048] Caco-2 cells that meet the compactness requirements in the Trans-well chamber were selected, the original culture medium in the chamber was aspirated and discarded, the PBS buffer was placed in a 37℃ water bath in advance, and then the impurities on the cell surface were washed away with pre-heated PBS buffer. AP→BL: 200μL of low, medium, and high concentrations (500, 2500, 10000ng / mL) of nucifera solution and 2500ng / mL of nucifera combined with verapamil mixture (verapamil 150.0ng / mL in the mixture) were added to the AP side as supply pools, and 400μL of PBS buffer was added to the corresponding BL side as receiving pools. 100μL of liquid sample was drawn from the receiving pool at 0.5 and 1.0h, respectively, and 100μL of PBS buffer was added to the receiving pool. The amount of nucifera transport in the sample was detected by LC-MS / MS, and its apparent permeability coefficient (Papp) was calculated. The above nucifera and verapamil concentrations were safe and non-toxic as detected by CCK8 kit. The larger the apparent permeability coefficient, the easier it is to absorb the liposomes.

[0049] Verification results:

[0050] Papp / cm / s (×10 -6 )(n=5)

[0051]

[0052] 2. Rat oral absorption experiment verification

[0053] 2.1 Establishment of HPLC method

[0054] 200 μL of blank rat serum was accurately drawn, and 20 μL of isoimperatorin (100 μg / mL) and 20 μL of a series of concentrations of nuciferine standard solution (1.0, 5.0, 10.0, 50.0, 100.0, 500.0 μg / mL) were added thereto, and the mixture was shaken and mixed, and 3 mL of ethyl acetate was added for extraction, vortexed for 1 min, and centrifuged at 4°C for 5 min (5000 r / min), and then the ethyl acetate layer was taken into a conical bottom glass tube, and the sample in the conical bottom glass tube was blown dry with nitrogen flow under water bath conditions. Subsequently, 100 μL of methanol was added to dissolve, and centrifuged again for 5 min (10000×g), and 20 μL of the upper layer liquid was taken for sampling and analysis.

[0055] High, medium and low concentrations (50, 5, 0.5 μg / mL) were selected to prepare serum quality control samples of nuciferine (50, 5, 0.5 μg / mL). The sample processing method was the same as above. Five injections were made at each concentration. The extraction recovery rate at different concentrations was calculated by the ratio of the peak area of ​​the drug in the sample to the peak area of ​​the drug directly dissolved in the chromatographic methanol. The intra-day precision and inter-day precision were also carried out on the same quality control sample. The relative standard deviation (RSD) was obtained by comparing the peak area of ​​5 consecutive injections within the day and between days. At the same time, the peak area was substituted into the standard curve equation to calculate the nuciferine concentration, which was compared with the added concentration to obtain the accuracy of the method.

[0056] Quality control samples (QC) of nuciferine with concentrations of 50, 5, and 0.5 μg / mL were prepared and stored at room temperature, 4°C, and -20°C, respectively. The sample processing method was the same as above, and each concentration was repeated 5 times. The detected drug peak area ratio was substituted into the standard curve equation, and the ratio of the obtained concentration to the added concentration was calculated. The change in nuciferine concentration under different storage conditions was calculated to reflect the sample stability.

[0057] 2.2 Sample collection and processing

[0058] Six SPF SD rats were gavaged with 100 mg / kg body weight of nanoliposome solutions of nuciferine prepared by different preparation methods, and blood was collected at 5min, 10min, 30min, 45min, 1h, 2h, 3h, 6h, 10h, and 24h after administration. Blank plasma was collected before administration. The collected blood was centrifuged at 5000r / min for 5min, 200μL of serum was taken in a blank centrifuge tube, 20μL of isoimperatorin internal standard solution was added thereto, and after oscillation and ultrasound, 20μL of the upper layer liquid was taken for sampling and analysis after treatment according to the "Sample Treatment Method under Item 2.1".

[0059] Pharmacokinetic parameters of different nanoliposomes in rats

[0060]

[0061]

[0062] Verification results: The smaller the absorption half-life and peak time, the better the absorption. The larger the peak concentration, the better the absorption. The larger the AUC, the better the bioavailability. It can be seen that the liposomes prepared by the formula of the present invention have good absorption and good bioavailability. The preparation of modified nanoparticles with bile acid-polyethylene glycol phospholipids can improve the bioavailability of ursolic acid and nuciferol; bile acid, polyethylene glycol phospholipids and soybean lecithin are composed, and the three have a synergistic effect on promoting the bioavailability of ursolic acid and nuciferol.

[0063] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the above embodiments do not limit the present invention in any form, and any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.

Claims

1. A bile acid-polyethylene glycol phospholipid compound liposome, characterized in that: The mass proportions are: 50 parts of ursolic acid, 50 parts of nuciferine, and 150 parts of phospholipids; the mass ratio of the phospholipids is: a mixture of bile acid, polyethylene glycol phospholipids and soybean phospholipids in a mass ratio of 1:2:

5.

2. A method for preparing bile acid-polyethylene glycol phospholipid compound liposomes, characterized in that: The steps include: Step 1, prepare materials according to the following formula, according to the mass parts: 50 parts of ursolic acid, 50 parts of nuciferol, and 150 parts of phospholipids; the phospholipids according to the mass ratio are: a mixture of bile acid, polyethylene glycol phospholipids and soybean phospholipids in a mass ratio of 1:2:5; heat ursolic acid and nuciferol in 2% acetic acid solution to 60-80°C to dissolve them completely; Step 2, weigh the prescribed amount of phospholipids and mix them evenly; Step 3, placing the phospholipid in a bottle, adding 200-300 parts of chloroform thereto, evaporating and removing all the chloroform, so that a transparent and uniform film is formed on the inner wall of the bottle; Step 4: Add ursolic acid and nuciferine dissolved in 2% acetic acid solution at 45-50°C into the bottle for hydration, and continue hydration for 1 hour; Step 5, performing ultrasonic demulsification, and continuing ultrasonication for 10 minutes to obtain bile acid-polyethylene glycol phospholipid composite liposomes.

3. The method for preparing a bile acid-polyethylene glycol phospholipid compound liposome according to claim 2, characterized in that: The evaporation in step 3 is carried out by rotary evaporation in a 40-50°C water bath.

4. The method for preparing bile acid-polyethylene glycol phospholipid compound liposome according to claim 2, characterized in that: The ultrasonic demulsification adopts a 500W cell disruptor.